| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
|
Cejalvo, Juan Miguel
|
|
2018
|
67 |
C |
p. 63-70
|
artikel
|
| 2 |
Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?
|
Gallo, Marco
|
|
2018
|
67 |
C |
p. 1-9
|
artikel
|
| 3 |
Editorial Board
|
|
|
2018
|
67 |
C |
p. ii
|
artikel
|
| 4 |
Estrogen receptor-negative progesterone receptor-positive breast cancer – “Nobody's land“ or just an artifact?
|
Kunc, Michał
|
|
2018
|
67 |
C |
p. 78-87
|
artikel
|
| 5 |
MAGE-A antigens as targets for cancer immunotherapy
|
Schooten, Erik
|
|
2018
|
67 |
C |
p. 54-62
|
artikel
|
| 6 |
Metabolomics in breast cancer: A decade in review
|
McCartney, Amelia
|
|
2018
|
67 |
C |
p. 88-96
|
artikel
|
| 7 |
Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research
|
Mosillo, Claudia
|
|
2018
|
67 |
C |
p. 29-33
|
artikel
|
| 8 |
The current evidence for a biomarker-based approach in cancer of unknown primary
|
El Rassy, Elie
|
|
2018
|
67 |
C |
p. 21-28
|
artikel
|
| 9 |
The management of adolescents and young adults with cancer
|
Hughes, Nicola
|
|
2018
|
67 |
C |
p. 45-53
|
artikel
|
| 10 |
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality
|
Papadimitriou, Marios
|
|
2018
|
67 |
C |
p. 34-44
|
artikel
|
| 11 |
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
|
Pondé, Noam
|
|
2018
|
67 |
C |
p. 10-20
|
artikel
|
| 12 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
|
Duchnowska, Renata
|
|
2018
|
67 |
C |
p. 71-77
|
artikel
|
Tijdschrift beschrijving